Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email p
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, today announces it has entered into a partnership with Tabula Rasa HealthCare® ( TRHC ) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety. Through this initiative, Physiomics personalised docetaxel model will be integrated into TRHC s market-leading precision dosing solution, DoseMeRx®. Both parties expect positive feedback from this initial trial with the next step being a commercial agreement.
Cancer remains one of the leading causes of death in developed countries and one of the most significant areas of spend for health systems. There are many effective cancer drugs; but, it is well established that, given the same dose, variations between individuals mean that different amounts of drug reach their tumours.